Treatment options for Duchenne muscular dystrophy

被引:23
作者
Ciafaloni, Emma [1 ]
Moxey, Richard T. [1 ]
机构
[1] Univ Rochester, Dept Neurol, Rochester, NY 14642 USA
关键词
D O I
10.1007/s11940-008-0010-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The main goal in the treatment of Duchenne muscular dystrophy (DMD) is to maintain ambulation for as long as possible and to anticipate and manage the associated complications, such as joint contractures, scoliosis, cardiomyopathy, respiratory insufficiency, and weight gain. Cognitive and behavioral symptoms occur in about one third of patients, and it is important to recognize and manage them promptly, developing an individualized plan at school and at home to maximize the patient's cognitive abilities. In the late phase of the disease, palliative care is of paramount importance. Corticosteroid therapy (prednisone and deflazacort) is the only effective pharmacologic treatment for DMD. Daily prednisone treatment increases muscle strength and function, improves pulmonary function, and significantly slows the progression of weakness. Deflazacort has a similar effect on muscle strength, but it is not available in the United States. Treatment with corticosteroid should be offered to all patients with DMD, but the beneficial effects and potential adverse effects should be fully discussed before treatment begins. The optimal dose of prednisone is 0.75 mg/kg per day, up to a maximum of 40 mg/d. If adverse effects occur, a decrease in dosage is appropriate. Monitoring of muscle function and adverse effects by a neurologist or neuromuscular specialist is strongly recommended. Physical and occupational therapists should be involved early in the treatment of patients with DMD to develop a program that includes heel cord stretching and exercise. In the later phases, these therapists can recommend adaptive equipment and maximize independence. Orthopedic consultation is important in monitoring and managing scoliosis and joint contractures in the nonambulatory phase of the disease. Pulmonary evaluation for ventilatory care is important; pulmonary consultation is essential when vital capacity declines. The use of assistive cough devices, nasal bilevel positive airway pressure, and tracheostomy must be discussed with patients and their families. For all patients with DMD, particularly those receiving prednisone, consultation with a dietitian is very helpful to control weight and maintain a healthy diet.
引用
收藏
页码:86 / 93
页数:8
相关论文
共 21 条
[1]   The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature [J].
Bakker, JPJ ;
de Groot, IJM ;
Beckerman, H ;
de Jong, BA ;
Lankhorst, GJ .
CLINICAL REHABILITATION, 2000, 14 (04) :343-359
[2]   American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation [J].
Birnkrant, David J. ;
Panitch, Howard B. ;
Benditt, Joshua O. ;
Boitano, Louis J. ;
Carter, Edward R. ;
Cwik, Valerie A. ;
Finder, Jonathan D. ;
Iannaccone, Susan T. ;
Jacobson, Lawrence E. ;
Kohn, Gary L. ;
Motoyama, Etsuro K. ;
Moxley, Richard T. ;
Schroth, Mary K. ;
Sharma, Girish D. ;
Sussman, Michael D. .
CHEST, 2007, 132 (06) :1977-1986
[3]   Functional improvement of dystrophic muscle by myostatin blockade [J].
Bogdanovich, S ;
Krag, TOB ;
Barton, ER ;
Morris, LD ;
Whittemore, LA ;
Ahima, RS ;
Khurana, TS .
NATURE, 2002, 420 (6914) :418-421
[4]   Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states [J].
Cohn, Ronald D. ;
van Erp, Christel ;
Habashi, Jennifer P. ;
Soleimani, Arshia A. ;
Klein, Erin C. ;
Lisi, Matthew T. ;
Gamradt, Matthew ;
Rhys, Colette M. ap ;
Holm, Tammy M. ;
Loeys, Bart L. ;
Ramirez, Francesco ;
Judge, Daniel P. ;
Ward, Christopher W. ;
Dietz, Harry C. .
NATURE MEDICINE, 2007, 13 (02) :204-210
[5]   Perindopril preventive treatment on mortality in Duchenne muscular dystrophy:: 10 years' follow-up [J].
Duboc, Denis ;
Meune, Christophe ;
Pierre, Bertrand ;
Wahbi, Karim ;
Eymard, Bruno ;
Toutain, Annick ;
Berard, Carole ;
Vaksmann, Guy ;
Weber, Simon ;
Becane, Henri-Marc .
AMERICAN HEART JOURNAL, 2007, 154 (03) :596-602
[6]  
Escolar D, 2006, ANN NEUROL, V60, pS132
[7]   CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy [J].
Escolar, DM ;
Buyse, G ;
Henricson, E ;
Leshner, R ;
Florence, J ;
Mayhew, J ;
Tesi-Rocha, C ;
Gorni, K ;
Pasquali, L ;
Patel, KM ;
McCarter, R ;
Huang, J ;
Mayhew, T ;
Bertorini, T ;
Carlo, J ;
Connolly, AM ;
Clemens, PR ;
Goemans, N ;
Iannaccone, ST ;
Igarashi, M ;
Nevo, Y ;
Pestronk, A ;
Subramony, SH ;
Vedanarayanan, VV ;
Wessel, H .
ANNALS OF NEUROLOGY, 2005, 58 (01) :151-155
[8]   Systemic delivery of genes to striated muscles using adeno-associated viral vectors [J].
Gregorevic, P ;
Blankinship, MJ ;
Allen, JM ;
Crawford, RW ;
Meuse, L ;
Miller, DG ;
Russell, DW ;
Chamberlain, JS .
NATURE MEDICINE, 2004, 10 (08) :828-834
[9]   Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers [J].
Hirawat, Samit ;
Welch, Ellen M. ;
Elfring, Gary L. ;
Northcutt, Valerie J. ;
Paushkin, Sergey ;
Hwang, Seongwoo ;
Leonard, Eileen M. ;
Almstead, Neil G. ;
Ju, William ;
Peltz, Stuart W. ;
Miller, Langdon L. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (04) :430-444
[10]   Predictive factors for the development of scoliosis in Duchenne muscular dystrophy [J].
Kinali, M. ;
Main, M. ;
Eliahoo, J. ;
Messina, S. ;
Knight, R. K. ;
Lehousky, J. ;
Edge, G. ;
Mercuri, E. ;
Manzur, A. Y. ;
Muntoni, F. .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2007, 11 (03) :160-166